Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Trichosanthis Pericarpium injection ameliorates non-alcoholic fatty liver disease via inhibiting the KLF6/ABCC5 pathway in mice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Dongsheng, Li Jiye, Wei Qianyi, Zhu Chunsheng, Zhang Xiaodan, Li Xiaoping, Guo Danfeng
Аннотация
BACKGROUND: Trichosanthis Pericarpium injection (TPI) exhibits notable therapeutic effects on cardiovascular disease caused by phlegm-turbidity (tan zhuo), yet its impact on non-alcoholic fatty liver disease (NAFLD) which has similarly resulted by phlegm-turbidity remains largely unexplored. This study investigates the ameliorative effects of TPI on NAFLD and elucidates its underlying mechanisms.
METHODS: This study was conducted both in vivo and in vitro using a mouse model of NAFLD and oleic acid (OA)-stimulated AML-12 cells, respectively. The chemical constituents of TPI were analyzed using UPLC-MS. Non-targeted metabolomics, transcriptome sequencing, molecular docking and surface plasmon resonance (SPR) were employed to identify gene and pathway alterations linked to lipid metabolism in the NAFLD model, and assess TPI's molecular and functional protective effects.
RESULTS: A total of 628 compounds were identified from TPI. TPI significantly ameliorated metabolic dysregulation and hepatic fat deposition in high-fat diet (HFD) mice. Similar protective effects were observed in OA-treated AML-12 cells. Metabolomic analysis identified significant changes in metabolites, with the ABC transporter pathway being the most affected. RT-qPCR and immunoblotting analysis revealed a substantial upregulation of ABCC5 in HFD mice, which was effectively suppressed by TPI. Transcriptomic analysis further confirmed the increased expression of KLF6 and ABCC5 in HFD group. Luciferase assays verified that KLF6 binds directly to the ABCC5 promoter, influencing lipid metabolism and contributing to NAFLD progression, while TPI inhibited KLF6's impact on ABCC5 transcriptional activity. Molecular docking and SPR showed that the active components of TPI-rutin, apigenin, and luteolin-form hydrogen bonds with specific amino acid residues of KLF6. Further mechanistic studies showed ABCC5 promoted cellular lipid deposition by suppressing glucagon-like peptide-1 (GLP-1) synthesis and secretion, whereas TPI enhanced their production and release.
CONCLUSIONS: In summary, TPI ameliorates NAFLD by mitigating hepatic lipid accumulation both in vivo and in vitro, through inhibition of the KLF6/ABCC5 pathway.
METHODS: This study was conducted both in vivo and in vitro using a mouse model of NAFLD and oleic acid (OA)-stimulated AML-12 cells, respectively. The chemical constituents of TPI were analyzed using UPLC-MS. Non-targeted metabolomics, transcriptome sequencing, molecular docking and surface plasmon resonance (SPR) were employed to identify gene and pathway alterations linked to lipid metabolism in the NAFLD model, and assess TPI's molecular and functional protective effects.
RESULTS: A total of 628 compounds were identified from TPI. TPI significantly ameliorated metabolic dysregulation and hepatic fat deposition in high-fat diet (HFD) mice. Similar protective effects were observed in OA-treated AML-12 cells. Metabolomic analysis identified significant changes in metabolites, with the ABC transporter pathway being the most affected. RT-qPCR and immunoblotting analysis revealed a substantial upregulation of ABCC5 in HFD mice, which was effectively suppressed by TPI. Transcriptomic analysis further confirmed the increased expression of KLF6 and ABCC5 in HFD group. Luciferase assays verified that KLF6 binds directly to the ABCC5 promoter, influencing lipid metabolism and contributing to NAFLD progression, while TPI inhibited KLF6's impact on ABCC5 transcriptional activity. Molecular docking and SPR showed that the active components of TPI-rutin, apigenin, and luteolin-form hydrogen bonds with specific amino acid residues of KLF6. Further mechanistic studies showed ABCC5 promoted cellular lipid deposition by suppressing glucagon-like peptide-1 (GLP-1) synthesis and secretion, whereas TPI enhanced their production and release.
CONCLUSIONS: In summary, TPI ameliorates NAFLD by mitigating hepatic lipid accumulation both in vivo and in vitro, through inhibition of the KLF6/ABCC5 pathway.